DailyIQ
|
Sector:HealthcareAll sectors
Last updated 41 days ago

AZN·AZN

$.
-. (-.%)
High
$185.13
Open
$182.78
Market Cap
213.02B
52W High
$15,730.00
Low
$179.94
P. Close
$185.67
P/E
27.60
52W Low
$10,104.00
Fwd P/E
23.14
DailyIQ Est.
$241.16
Technical Score (1D)
27
SELL
News Sentiment
76
BULLISH
The recent liver‑cancer efficacy data from AstraZeneca’s trials shows significant improvement in patient outcomes, which bolsters the company’s oncology sales outlook and could influence investor sentiment, so traders should monitor the next data release and any regulatory filings. In the EMERALD‑3 Phase III trial, IMFINZI® plus IMJUDO® combined with lenvatinib and TACE reduced disease progression or death by 30% in embolization‑eligible unresectable liver cancer, strengthening the pipeline and supporting the $40 B oncology revenue target, so watch for FDA review timelines and potential launch dates. The combined evidence from both studies underpins the projected $40 B oncology sales, indicating a robust growth trajectory for the next 1–10 trading days, so keep an eye on any updates to the sales forecast. If the FDA approves the combination therapy, the commercial launch could accelerate revenue realization, so traders should watch for FDA decision announcements. Any delay in regulatory approval could temper the optimistic outlook, so monitor the FDA docket for any pending decisions. Upcoming data releases from the liver‑cancer trials will provide further confirmation of efficacy, so watch the company’s earnings releases and conference calls. The positive trial results also enhance the company’s competitive positioning against other oncology players, so watch for any market reactions to competitor news. Overall, the recent liver‑cancer data and Phase III trial results reinforce the company’s growth narrative, so traders should watch for any subsequent regulatory or commercial milestones that could validate the $40 B target.
Earnings Summary
AstraZeneca PLC is a global biopharmaceutical company engaged in the research, development, production, and commercialization of prescription medicines across key therapeutic areas including oncology, cardiovascular, renal and metabolism, and respiratory & immunology. Operating within the Healthcare sector, specifically the Drug Manufacturers - General industry, AstraZeneca focuses on delivering innovative treatments to patients worldwide through strategic partnerships and direct engagement with healthcare professionals. The company's recent quarterly performance shows a mixed pattern of exceeding or meeting analyst expectations for Earnings Per Share (EPS). In Q3 2025, AZN reported EPS of $1.19, surpassing the estimate of $1.13, with revenue at $15.19 billion. This followed Q2 2025, where EPS was $1.085 against an estimate of $1.46, and revenue was $14.46 billion. Prior to this, Q1 2025 saw EPS of $1.245, beating the estimate of $1.12, with revenue at $13.59 billion, and Q4 2024 reported EPS of $1.045, slightly above the estimate of $1.04, with revenue at $14.89 billion. Revenue has shown a general upward trend across the reported quarters, with Q1 2025 revenue at $13.59 billion, Q2 2025 at $14.46 billion, Q3 2025 at $15.19 billion, and projected Q1 2026 revenue at $15.36 billion, and Q2 2026 at $15.94 billion. Historically, AstraZeneca has demonstrated consistent revenue growth, with recent quarters generally showing year-over-year increases, driven by its key drug portfolios. The company has a track record of meeting or beating analyst EPS estimates in most of the recent quarters, with a notable beat in Q1 2025 and Q3 2025, and a slight beat in Q4 2024, though Q2 2025 saw a miss. Recent news highlights positive developments for Enhertu, with a recommendation for approval in the EU for unresectable or metastatic HER2-positive solid tumors, and expanded indications for Datopotamab deruxtecan in breast cancer, underscoring progress in its oncology pipeline. The company also reported strong Q1 revenue growth driven by its Oncology and Rare Disease segments and reaffirmed its 2026 guidance. Investors will be watching for the formal EU approval of Enhertu and the market uptake of Datroway, as well as continued performance updates from the Oncology and Rare Disease portfolios, and the company's ability to meet its mid-to-high single-digit revenue and low double-digit EPS growth targets for 2026.

EPS

EstBeatMiss
$0.97$1.11$1.25$1.39$1.53Q4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$1.22 - -
Q3'25$1.13$1.19+4.9%
Q2'25$1.46$1.08-25.9%
Q1'25$1.12$1.25+11.6%
Q4'24$1.04$1.04+0.8%

Revenue

EstBeatMiss
$13.3B$13.9B$14.5B$15.1B$15.6BQ4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$15.4B - -
Q3'25 - $15.2B -
Q2'25 - $14.5B -
Q1'25 - $13.6B -
Q4'24 - $14.9B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AZN Stock Snapshot

AZN is currently trading at $180.06, giving AZN a market cap of 213.02B and a P/E ratio of 27.6. Today's range spans $179.94–$185.13, with shares opening at $182.78 and moving down $5.61 (3.0%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 76/100.

Over the past year AZN has traded between $10104.00 and $15730.00 - the current price is -98.2% off the 52-week low and -98.9% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $224.49 (range $184.00–$245.00), implying upside of +24.7%.

Sector rotation is working against AZN - large-cap, Healthcare, 213.02B market cap. Technical score 27/100 (SELL), sentiment bullish (76/100), price $180.06 (near 52-week lows). (P/E: 27.6) When capital rotates out of a sector, large-cap names with bearish technicals are the first to absorb the selling. Annual range $10104.00–$15730.00 frames where the next potential demand zone resides.

When a large-cap Healthcare name with 213.02B in capitalization prints a SELL signal (27/100) alongside bullish news sentiment (76/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $180.06 (near 52-week lows in the $10104.00–$15730.00 range), the structural support levels are where that sponsorship question gets answered.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0 articles